On Thursday, Moderna Inc (NASDAQ:MRNA) stock plunged as the company lowered its 2024 sales guidance due to weaker demand for its COVID-19 vaccines. Moderna now projects 2024 net sales of between $3 billion and $3.5 billion from its respiratory franchise versus previous guidance of about $4 billion, citing low EU sales in 2024, potential revenue deferrals for certain international sales into 2025, and an increasingly competitive environment for respiratory vaccines in the U.S. Also Read: European Commission Faces Court ...